Zenas BioPharma (ZBIO) Director Christy Oliger Receives 37,000-Share Award

What Happened
Christy J. Oliger, a director of Zenas BioPharma, was granted a derivative equity award for 37,000 shares on September 1, 2026. The filing shows an acquisition coded as "A" (award/grant) at $0.00 per share (no cash paid). This is an equity compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-01; Form 4 filed: 2026-09-02 (timely filing).
• Security: derivative award for 37,000 shares; reported price: $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The award vests in equal annual installments over three years beginning on September 1, 2027 (the first anniversary of the vesting commencement date), subject to continued service.
• No 10b5-1 plan, tax withholding, cashless exercise, or sale was reported in the provided information.

Context
This is a standard equity compensation grant to a board member — common for aligning directors with shareholder interests. Because it is a grant (derivative award) rather than a purchase or sale, it should be viewed as compensation-related, not a direct market signal of the insider buying or selling shares.